

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣葯業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1681)

**DELAY IN DESPATCH OF CIRCULAR
REGARDING
(1) PROPOSED OFF-MARKET SHARE BUY-BACK
AND CONNECTED TRANSACTION;
(2) APPLICATION FOR WHITEWASH WAIVER; AND
(3) PROPOSAL FOR DISTRIBUTION OF SPECIAL DIVIDEND**

Financial Adviser to the Company



BNP PARIBAS

BNP Paribas Securities (Asia) Limited

Reference is made to the announcement issued by Consun Pharmaceutical Group Limited (the “**Company**”) dated 6 February 2017 (the “**Announcement**”) in relation to, among other things, the Share Buy-back and the Whitewash Waiver. Unless otherwise specified, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

Pursuant to Rule 8.2 of the Takeovers Code, the Circular containing, among other things, details of the Share Buy-back Agreement and the Whitewash Waiver, the letter from the Independent Board Committee giving its recommendation to the Disinterested Shareholders on the Share Buy-back Agreement and the Whitewash Waiver, the letter from the independent financial adviser containing its advice to the Independent Board Committee relating to the Share Buy-back Agreement and the Whitewash Waiver, the notice of the EGM and other information as required under the Listing Rules, the Takeovers Code and the Buy-backs Code is required to be despatched to the Shareholders within 21 days from the date of the Announcement, which is on or before 27 February 2017. As additional time is required to finalise certain information to be included in the Circular, including the letter from the Independent Financial Adviser to the Independent Board Committee and certain financial information of the Group, an application has been made to the Executive pursuant to Rule 8.2 of the Takeovers Code for its consent to extend the deadline for the despatch of the Circular to a date falling on or before 20 March 2017, and the Executive has indicated that it is minded to grant its consent for such extension.

By order of the Board
Consun Pharmaceutical Group Limited
AN Yubao
Chairman

Hong Kong, 27 February 2017

As at the date of this announcement, the Board comprises Mr. AN Yubao, Ms. LI Qian and Professor ZHU Quan as executive Directors; Mr. WANG Shunlong and Mr. LIN Sheng as non-executive Directors; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHENG Xinxin as independent non-executive Directors.

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.